Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).

Robert Chen,Stephen Maxted Ansell,Andrea Gallamini,Joseph M. Connors,Kerry J. Savage,Graham P. Collins,Andrew Grigg,Anna Sureda,Nilanjan Ghosh,Tatyana Feldman,Alexander Fosså,Evren Ozdemir,Fritz Offner,Gerald Engley,Keenan Fenton,Shih-Yuan Lee,Hina Jolin,Ashish Gautam,Martin Hutchings

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).

2018

Robert Chen
Stephen Maxted Ansell
Andrea Gallamini
Joseph M. Connors
Kerry J. Savage
Graham P. Collins
Andrew Grigg
Anna Sureda
Nilanjan Ghosh
Tatyana Feldman
Alexander Fosså
Evren Ozdemir
Fritz Offner
Gerald Engley
Keenan Fenton
Shih-Yuan Lee
Hina Jolin
Ashish Gautam
Martin Hutchings

7539Background: The ECHELON-1 trial demonstrated improved outcomes for patients (pts) with advanced HL who received frontline A+AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) vs A...

Keywords:

Lymphoma
Progression-free survival
Pathology
Brentuximab vedotin
Cancer research
Medicine
Chemotherapy
Doxorubicin
hodgkin lymphoma
Oncology
Internal medicine
Dacarbazine
Vinblastine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations